...Due Inc., a separate subsidiary that houses cGAS...

...DISEASE CATEGORY: Gastrointestinal INDICATION: Colitis Colitis may be treatable by targeting cGAS, a cytosolic DNA sensor...
...the cGAS product cGAMP in colon tissue. In wild-type mice exposed to the chemical, a cGAS...
...weight loss, clinical disease scores and histological signs of inflammation and intestinal architecture damage. The cGAS...

...DISEASE CATEGORY: Hepatic INDICATION: Liver disease Targeting the cGAS-IRF3 signaling pathway by inhibiting cGAS or the...
...GJB1 could treat alcohol-related liver disease. In liver samples from alcoholic-related liver disease patients, high cGAS...
...more severe disease. In mice with liver disease due to alcohol consumption, systemic or hepatocyte-specific cGAS...

...The biotech has a STING agonist that is partnered with Novartis AG (NYSE:NVS; SIX:NOVN), a cGAS-STING...
...million. Targets APRIL (TNFSF13) - Tumor necrosis factor (TNF) ligand superfamily member 13 cGAS - cGAMP synthase...

...entered a collaboration and acquisition option deal for the IFM Due subsidiary, which is developing cGAS...
...do deal-making.” Sheail expects more deals to close in the coming months. Targets cGAS - cGAMP synthase...

...GF Securities, and Arch Venture Partners Executive Chair: Sandra Peterson Patents: Undisclosed Targets cGas - cGAMP synthase...

...up to $840 million in upfront and milestone payments. IFM Due is developing antagonists of cGAS...
...post of executive chairman. Seidel will also sit on the company’s board. Targets: cGAS - cGAMP synthase...

...intends to develop first-in-class drugs that target protein-protein interactions of the STING signaling pathway. The cGAS-STING...
...fragments of abnormal DNA, such as microbial or damaged human DNA, and triggers inflammatory signaling. cGAS...
...board will include Tobin, Døssing, Wellington’s Regina Hodits and Sunstone’s Sten Verland. Targets: cGAS - cGAMP synthase...

...undisclosed but comparable to a "very healthy VC round." IFM Due is developing antagonists of cGAS...
...than agonize, the STING pathway (see "IFM Launches Subsidiary for cGAS, STING Inhibitors" ). The cGAS-STING...
...a new unit early next quarter to develop its non-NLRP3 inflammasome programs. Targets: cGAS - cGAMP synthase...

...compound Small molecule inhibitors of human cGAS could be used to probe the role of cGAS-dependent...
...line and in primary human macrophages, the cGAS inhibitors inhibited interferon β (IFNB1) expression downstream cGAS...
...in animal models of inflammatory diseases. DESCRIPTION: Human cGAMP synthase (cGAS) inhibitors for probing the role of cGAS-dependent...